Skip to main content

Pharmacologic Approaches to CDH: Evidence and Outcomes

  • Chapter
  • First Online:
Chronic Headache

Abstract

Chronic daily headache (CDH) is a highly prevalent condition that severely affects patient’s lives. Most patients with CDH experience chronic migraine (CM). The management of these patients is complex and includes acute and preventive pharmacological treatment. In CDH, the use of acute medication should be restricted to avoid the risk of medication-overuse headache. However, the use of preventive medication should be considered in all patients with CDH. There are few studies investigating the role of preventives in CDH, and the majority have CM. Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of CM. There are other neuromodulators, beta-blockers, calcium channel blockers, or antidepressants useful in the management of this population of patients. We will present evidence for the efficacy of each drug and for recommended use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.

    Article  PubMed  CAS  Google Scholar 

  2. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23(8):820–4.

    Article  PubMed  CAS  Google Scholar 

  3. Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016;20(1):6.

    Article  PubMed  Google Scholar 

  4. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1–2):81–9.

    Article  PubMed  CAS  Google Scholar 

  5. Mathew NT, Kurman R, Perez F. Drug induced refractory headache--clinical features and management. Headache. 1990;30(10):634–8.

    Article  PubMed  CAS  Google Scholar 

  6. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the head-HUNT study. Neurology. 2003;61(2):160–4.

    Article  PubMed  Google Scholar 

  7. Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007;7(6):383–93.

    Article  PubMed  CAS  Google Scholar 

  8. Becker WJ. The diagnosis and management of chronic migraine in primary care. Headache. 2017;57(9):1471–81.

    Article  PubMed  Google Scholar 

  9. Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache. 2016;56(3):603–15.

    Article  PubMed  Google Scholar 

  10. He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Aurora SK, Brin MF. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;57(1):109–25.

    Article  PubMed  Google Scholar 

  12. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.

    Article  PubMed  Google Scholar 

  13. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.

    Article  PubMed  Google Scholar 

  14. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47(1):13–21.

    Article  PubMed  Google Scholar 

  15. Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29(5):269–75.

    Article  PubMed  CAS  Google Scholar 

  16. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31(1):18–30.

    Article  PubMed  Google Scholar 

  17. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73.

    Article  PubMed  CAS  Google Scholar 

  18. Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57(1):165–78.

    Article  PubMed  Google Scholar 

  19. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–64.

    Article  PubMed  CAS  Google Scholar 

  20. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.

    Article  PubMed  CAS  Google Scholar 

  22. Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–408.

    Article  PubMed  Google Scholar 

  23. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62.

    Article  PubMed  Google Scholar 

  24. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–8.

    Article  PubMed  CAS  Google Scholar 

  25. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281–6.

    Article  PubMed  CAS  Google Scholar 

  26. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.

    Article  PubMed  CAS  Google Scholar 

  27. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(8):1289–97.

    Article  PubMed  CAS  Google Scholar 

  29. Gursoy AE, Ertas M. Prophylactic treatment of migraine. Noro Psikiyatr Ars. 2013;50(Suppl 1):S30–S5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973–89.

    Google Scholar 

  31. Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: what is the evidence? Pain Med. 2016;17(1):162–71.

    PubMed  Google Scholar 

  33. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28(6):585–97.

    Article  PubMed  CAS  Google Scholar 

  34. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.

    Article  PubMed  CAS  Google Scholar 

  35. Pascual-Gomez J, Alana-Garcia M, Oterino A, Leira R, Lainez-Andres JM. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev Neurol. 2008;47(9):449–51.

    PubMed  CAS  Google Scholar 

  36. Pascual-Gomez J, Gracia-Naya M, Leira R, Mateos V, Alvaro-Gonzalez LC, Hernando I, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol. 2010;50(3):129–32.

    PubMed  Google Scholar 

  37. Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache. 2011;51(2):287–91.

    Article  PubMed  Google Scholar 

  38. Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011;34(4):174–7.

    Article  PubMed  CAS  Google Scholar 

  39. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (the Australian KEPPRA headache trial [AUS-KHT]). Cephalalgia. 2011;31(5):530–6.

    Article  PubMed  Google Scholar 

  40. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–32.

    Article  PubMed  Google Scholar 

  41. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23(10):961–2.

    Article  PubMed  CAS  Google Scholar 

  42. Pascual J. Combination therapy for chronic migraine: bad news but not the last word. Neurology. 2012;78(13):940–1.

    Article  PubMed  Google Scholar 

  43. Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus. 2013;2:479.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003;7(1):51–4.

    Article  PubMed  Google Scholar 

  45. Freitag FG, Lake A 3rd, Lipton R, Cady R, Diamond S, Silberstein S, et al. Inpatient treatment of headache: an evidence-based assessment. Headache. 2004;44(4):342–60.

    Article  PubMed  Google Scholar 

  46. Doyle Strauss L, Weizenbaum E, Loder EW, Rizzoli PB. Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study. Headache. 2016;56(10):1626–34.

    Article  PubMed  Google Scholar 

  47. Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type a versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463–6.

    Article  PubMed  Google Scholar 

  48. Couch JR. Amitriptyline versus placebo study G. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33–51.

    Article  PubMed  Google Scholar 

  49. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.

    Article  PubMed  CAS  Google Scholar 

  50. Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53(1):168–76.

    Article  PubMed  Google Scholar 

  51. Saper JR, Silberstein SD, Lake AE 3rd, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34(9):497–502.

    Article  PubMed  CAS  Google Scholar 

  52. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology. 2012;78(17):1337–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107(1):44–8.

    Article  PubMed  Google Scholar 

  54. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32(5):254–8.

    Article  PubMed  CAS  Google Scholar 

  55. Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. Duloxetine in the treatment of chronic migraine. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):49–54.

    PubMed  CAS  Google Scholar 

  56. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008;69(9):1449–54.

    Article  PubMed  CAS  Google Scholar 

  57. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache. 2001;41(5):465–74.

    Article  PubMed  CAS  Google Scholar 

  58. Gracia-Naya M, Rios C, Garcia-Gomara MJ, Sanchez-Valiente S, Mauri-Llerda JA, Santos-Lasaosa S, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Rev Neurol. 2013;57(8):347–53.

    PubMed  Google Scholar 

  59. Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand. 2017;135(4):476–83.

    Article  PubMed  CAS  Google Scholar 

  60. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–9.

    Article  PubMed  CAS  Google Scholar 

  61. Feher G, Pusch G. Role of antihypertensive drugs in the treatment of migraine. Orv Hetil. 2015;156(5):179–85.

    Article  PubMed  Google Scholar 

  62. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470–82.

    Article  PubMed  Google Scholar 

  63. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.

    Article  PubMed  Google Scholar 

  64. Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17(1):106.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache. 2015;55(4):529–42.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Bratbak DF, Nordgard S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017;37(4):356–64.

    Article  PubMed  Google Scholar 

  67. Saracco MG, Valfre W, Cavallini M, Aguggia M. Greater occipital nerve block in chronic migraine. Neurol Sci. 2010;31(Suppl 1):S179–80.

    Article  PubMed  Google Scholar 

  68. Dilli E, Halker R, Vargas B, Hentz J, Radam T, Rogers R, et al. Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. Cephalalgia. 2015;35(11):959–68.

    Article  PubMed  Google Scholar 

  69. Inan LE, Inan N, Karadas O, Gul HL, Erdemoglu AK, Turkel Y, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015;132(4):270–7.

    Article  PubMed  CAS  Google Scholar 

  70. Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand. 2016;136(2):138–44.

    Article  PubMed  CAS  Google Scholar 

  71. Cuadrado ML, Aledo-Serrano A, Navarro P, Lopez-Ruiz P, Fernandez-de-Las-Penas C, Gonzalez-Suarez I, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2016;37(9):864–72.

    Article  PubMed  Google Scholar 

  72. Cernuda-Morollon E, Pascual J. Something's moving in chronic migraine. Rev Neurol. 2014;58(1):1–3.

    PubMed  Google Scholar 

  73. D. Ezpeleta PPR. Guías diagnósticas y terpeútica de la Sociedad Española de Neurología 2015. 3. Guía oficial de práctica clínica en cefaleas2015 2015.

    Google Scholar 

  74. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.

    Article  PubMed  CAS  Google Scholar 

  75. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.

    Article  PubMed  CAS  Google Scholar 

  76. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.

    Article  PubMed  Google Scholar 

  77. Lia C, Tosi P, Giardini G, Caligiana L, Bottacchi E. Onabotulinumtoxin a for prophylaxis in chronic migraine: preliminary data from headache regional Centre of Aosta valley. Neurol Sci. 2014;35(Suppl 1):175–6.

    Article  PubMed  Google Scholar 

  78. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from hull, U.K. J Headache Pain. 2014;15:54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Grazzi L, Usai S. Onabotulinum toxin a (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci. 2015;36(Suppl 1):33–5.

    Article  PubMed  Google Scholar 

  80. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1–2):48–56.

    Article  PubMed  CAS  Google Scholar 

  81. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-a in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;8:79–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA injection on depression in chronic migraine. Headache. 2015;55(9):1218–24.

    Article  PubMed  Google Scholar 

  84. Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001.

    Article  PubMed  Google Scholar 

  85. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736–45.

    Article  PubMed  CAS  Google Scholar 

  86. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21–32.

    Article  PubMed  Google Scholar 

  87. Castrillo Sanz A, Morollon Sanchez-Mateos N, Simonet Hernandez C, Fernandez Rodriguez B, Cerdan Santacruz D, Mendoza Rodriguez A, et al. Experience with botulinum toxin in chronic migraine. Neurologia. 2016;S0213-4853(16):30209–2.

    Google Scholar 

  88. Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq Neuropsiquiatr. 2017;75(3):153–9.

    Article  PubMed  Google Scholar 

  89. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489–96.

    Article  PubMed  Google Scholar 

  90. Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010;68(1):81–91.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Pagola I, Esteve-Belloch P, Palma JA, Luquin MR, Riverol M, Martinez-Vila E, et al. Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine. Rev Neurol. 2014;58(6):241–6.

    PubMed  Google Scholar 

  92. Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156(5):820–4.

    Article  PubMed  CAS  Google Scholar 

  93. Pedraza MI, de la Cruz C, Ruiz M, Lopez-Mesonero L, Martinez E, de Lera M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015;4:176.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Oterino A, Ramon C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain. 2011;12(2):235–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35(10):864–8.

    Article  PubMed  Google Scholar 

  96. Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD. Onabotulinumtoxin-a treatment in Greek patients with chronic migraine. J Headache Pain. 2016;17(1):84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851–9.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15:100.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Aicua-Rapun I, Martinez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, et al. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin a during more than one year. J Headache Pain. 2016;17(1):112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.

    Article  PubMed  Google Scholar 

  101. Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.

    Article  PubMed  Google Scholar 

  102. Barbanti P, Aurilia C, Fofi L, Egeo G, Ferroni P. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurol Sci. 2017;38(Suppl 1):31–5.

    Article  PubMed  Google Scholar 

  103. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6(6):534–47. https://doi.org/10.1002/cpdd.345.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Hou M, Xing H, Cai Y, Li B, Wang X, Li P, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18(1):42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87(1):41–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miguel J. A. Láinez .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Láinez, M.J.A., Mínguez-Olaondo, A. (2019). Pharmacologic Approaches to CDH: Evidence and Outcomes. In: Green, M., Cowan, R., Freitag, F. (eds) Chronic Headache. Springer, Cham. https://doi.org/10.1007/978-3-319-91491-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91491-6_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91490-9

  • Online ISBN: 978-3-319-91491-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics